- idUS
- Listar por autor
Listar por autor "Guerra Veloz, María Fernanda"
Mostrando ítems 1-7 de 7
-
Artículo
Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice
Valdés Delgado, Teresa; Guerra Veloz, María Fernanda; Castro Laria, Luisa; Maldonado Pérez, Belén; Perea Amarillo, Raúl; Merino Bohórquez, Vicente; Sáez, Antonia; Caunedo Álvarez, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2020)Introduction: between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Ther apeutic ...
-
Artículo
Evolution of the incidence of inflammatory bowel disease in Southern Spain
Chaaro Benallal, Dina; Guerra Veloz, María Fernanda; Argüelles Arias, Federico; Benítez, José Manuel; Perea Amarillo, Raúl; Iglesias, Eva; Vilches Arenas, Ángel; Romero Gómez, Manuel (Aran Ediciones S.A., 2017)Background: The incidence of inflammatory bowel disease is increasing in Europe and in Spain. However, there is no recent ...
-
Artículo
Liver manifestations in COVID-19 and the influence of pre-existing liver disease in the course of the infection
Guerra Veloz, María Fernanda; Cordero Ruiz, Patricia; Ríos-Villegas, María José; del Pino Bellido, Pilar; Bravo-Ferrer, José; Gálvez Cordero, Rocio; Cadena Herrera, María Lorena; Vías Parrado, Carmen; Bellido Muñoz, Francisco; Vega Rodríguez, Francisco; Caunedo Álvarez, Ángel; Rodríguez-Baño, Jesús; Carmona Soria, Isabel (Arán Ediciones, S.L., 2021)Introduction: patients with advanced chronic liver disease (CLD) may be at an increased risk of a severe course due ...
-
Artículo
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
Guerra Veloz, María Fernanda; Belvis Jiménez, María Inmaculada; Valdés Delgado, Teresa; Castro Laria, Luisa; Maldonado Pérez, Belén; Perea Amarillo, Raúl; Merino Bohórquez, Vicente; Caunedo Álvarez, Ángel; Vilches Arenas, Ángel; Argüelles Arias, Federico (Original Research, 2019)Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated ...
-
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
Guerra Veloz, María Fernanda; Vázquez Morón, Juan María; Belvis Jiménez, María Inmaculada; Pallares Manrique, Héctor; Valdés Delgado, Teresa; Castro Laria, Luisa; Merino Bohórquez, Vicente; Vilches Arenas, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2018)Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of ...
-
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Argüelles Arias, Federico; Guerra Veloz, María Fernanda; Perea Amarillo, Raúl; Vilches Arenas, Ángel; Castro Laria, Luisa; Maldonado Pérez, Belén; Merino Bohórquez, Vicente; Romero Gómez, Manuel (Lippincott Williams & Wilkins, 2017)Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory ...
-
Tesis Doctoral
Valoración de la eficacia de Infliximab biosimilar (CT-P13, remsima®) frente al Infliiximab original (Remicade®) en pacientes con enfermedad inflamatoria intestinal.
Guerra Veloz, María Fernanda (2018-05-16)Introducción: las terapias biológicas, particularmente agentes anti-TNF alfa, han revolucionado el enfoque terapéutico de ...